from the newsletter
In preparation for the potential move to a Phase 2 trial for our
CHM CLTX CAR-T technology targeting recurrent / progressive
glioblastoma, the team continues to prepare to expand the Phase 1B
trial at Sarah Canon Cancer Centre in Texas (NCT05627323).Based
on advice from our experts we are in the process of making some
adjustments to the way the CLTX CAR-T is delivered
Rebecca is impressive, no mucking around. Thought Jen was the best, Rebecca seems easily topping her.
GLTA
from the newsletterIn preparation for the potential move to a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |